In this report, we cover catalysts from 22 drugs, devices, diagnostics, and deals expected to occur in Q2 2024. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.
